文献速递头颈外科咽喉与嗓音

现代放疗时代T3期声门上喉癌的肿瘤体积研究:加拿大头颈协作研究计划

Tumor volumes in T3 supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative.
PubMed 文献 · Head Neck · 2023-12-20

该回顾性队列研究纳入2002至2018年加拿大七家区域癌症中心的239例T3 N0-3M0声门上喉癌患者,均接受调强放疗。原发肿瘤体积每增加1 cm³与更差的总生存(HR 1.01,95% CI 1.00-1.02,p<0.01)和无病生存(HR 1.01,95% CI 1.00-1.02,p=0.02)相关,未见明确阈值。

要点

  • 239例T3 N0-3M0声门上喉癌接受调强放疗,平均肿瘤体积11.37 cm³。
  • 肿瘤体积每增加1 cm³,总生存HR 1.01(95% CI 1.00-1.02,p<0.01)。
  • 肿瘤体积每增加1 cm³,无病生存HR 1.01(95% CI 1.00-1.02,p=0.02),无明确阈值。

核心结论

  • 在T3声门上喉癌接受调强放疗的患者中,原发肿瘤体积增加与更差的总生存和无病生存相关,未见明确阈值。
  • 作者认为,肿瘤较大且基线喉功能差的患者可能从 upfront 喉切除术联合辅助放疗中获益。

研究设计与样本

  • 回顾性队列研究,纳入2002至2018年加拿大七家区域癌症中心的239例T3 N0-3M0声门上喉癌患者。
  • 临床数据来自患者记录,声门上肿瘤体积由神经放射科医生在诊断影像上测量。
  • 采用Kaplan-Meier法计算生存概率,采用限制性立方样条Cox比例风险回归分析肿瘤体积与总生存和无病生存的关联。

主要发现

  • 参与者平均(SD)年龄65.2(9.4)岁,176例(73.6%)为男性,90例(38%)为N0,151例(64%)接受同期全身治疗。
  • 平均肿瘤体积(SD)为11.37(12.11)cm³,平均随访(SD)3.28(2.60)年。
  • 2年总生存率为72.7%(95% CI 66.9%-78.9%),2年无病生存率为53.6%(95% CI 47.4%-60.6%)。
  • 肿瘤体积每增加1 cm³与更差的总生存相关(HR 1.01,95% CI 1.00-1.02,p<0.01)。
  • 肿瘤体积每增加1 cm³与更差的无病生存相关(HR 1.01,95% CI 1.00-1.02,p=0.02)。

临床怎么用

  • 作者认为,肿瘤较大且基线喉功能差的患者可能从 upfront 喉切除术联合辅助放疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the association of primary tumor volume (TV) with overall survival (OS) and disease-free survival (DFS) in T3 N0-3M0 supraglottic cancers treated with intensity-modulated radiotherapy (IMRT). METHODS: This was a retrospective cohort study involving 239 patients diagnosed with T3 N0-3M0 supraglottic cancers between 2002 and 2018 from seven regional cancer centers in Canada. Clinical data were obtained from the patient records. Supraglottic TV was measured by neuroradiologists on diagnostic imaging. Kaplan-Meier method was used for survival probabilities, and a restricted cubic spline Cox proportional hazards regression analysis was used to analyze TV associations with OS and DFS. RESULTS: Mean (SD) of participants was 65.2 (9.4) years; 176 (73.6%) participants were male. 90 (38%) were N0, and 151 (64%) received concurrent systemic therapy. Mean TV (SD) was 11.37 (12.11) cm3 . With mean follow up (SD) of 3.28 (2.60) years, 2-year OS was 72.7% (95% CI 66.9%-78.9%) and DFS was 53.6% (47.4%-60.6%). Increasing TV was associated (per cm3 increase) with worse OS (HR, 1.01, 95% CI 1.00-1.02, p < 0.01) and DFS (HR, 1.01, 95% CI 1.00-1.02, p = 0.02). CONCLUSIONS: Increasing primary tumor volume is associated with worse OS and DFS in T3 supraglottic cancers treated with IMRT, with no clear threshold. The findings suggest that patients with larger tumors and poor baseline laryngeal function may benefit from upfront laryngectomy with adjuvant radiotherapy.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Malik NH, Fu R, Hainc N, et al. Tumor volumes in T3 supraglottic cancers treated with radiotherapy in the modern era: A study of the Canadian Head & Neck Collaborative Research Initiative. Head Neck. 2023. PMID: 38116716. doi:10.1002/hed.27608

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。